Trial Profile
A Study of Epigenetic Priming Using Decitabine With Front Line Induction Chemotherapy Compared With Immediate Induction Chemotherapy in Pediatric Acute Myelogenous Leukemia (AML) Subjects.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Decitabine (Primary) ; Cytarabine; Daunorubicin
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- Sponsors Eisai Inc; Eisai Medical Research
- 17 Nov 2010 Status changed from not yet recruiting to discontinued as reported by ClinicalTrials.gov.
- 13 Apr 2010 Planned initiation date changed from 1 Feb 2010 to 1 Jun 2010 as reported by ClinicalTrials.gov.
- 12 Aug 2009 Planned initiation date changed from 1 Oct 2009 to 1 Feb 2010 as reported by ClinicalTrials.gov.